Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MitoQ in COPD
NCT05605548Phase 1Terminated
- Sponsor
- Virginia Commonwealth University
- Start
- Feb 2023
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial (2 arms), sponsored by Virginia Commonwealth University. Primary endpoints: Change in vascular function at 6 weeks, Change in Skeletal Muscle Oxygenation at 6 weeks and 1 more. Started Feb 2023; status: terminated.
Beyond the preview
Go deeper on NCT05605548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05605548.